JCCC Leaders in the Field Seminar featuring Dr. Richard Klausner
Promises and challenges of cancer detection: the journey of GRAIL
- Date: March 05, 2020 12:00 PM - 1:00 PM
- Location: 53-105 CHS
10833 Le Conte Ave.
Los Angeles, California 90095
Richard Klausner, M.D.
Founder and Director, Juno Therapeutics
Founder and Director, GRAIL
Executive Chairman, Wisdo
Dr. Richard Klausner has provided valuable mechanistic insights into cellular processes such as intracellular trafficking, translation, and protein assembly. He has also contributed to the understanding of post-translational gene regulation mechanisms through his study of iron metabolism. Furthermore, his investigations into the von Hippel-Lindau (VHL) protein has led to further classification of the protein’s tumor suppressive function in the context of renal cell carcinoma. His discovery of the T Cell Zeta chain and how T cells are activated was the basic science breakthrough that lead to successful cell- based CAR-T cancer therapy.
Light lunch served
Sponsored by the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology research program